ArticleJournal of gastrointestinal oncology2021

Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report.

Douglas Rubinson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.